TianhongLiMD
Oncology • Sacramento, CAAssistant Professor, Internal Medicine, UC, Davis School of Medicine
Dr. Li is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
2278 45th Street
Sacramento, CA 95817Phone+1 916-734-5959Fax+1 916-703-5265
Education & Training
Montefiore Medical Center/Albert Einstein College of Medicine (Moses and Weiler Campuses)Fellowship, Hematology and Medical Oncology, 2000 - 2003
Icahn School of Medicine at Mount Sinai/Beth IsraelResidency, Internal Medicine, 1997 - 2000
Beijing Medical UniversityClass of 1989
Certifications & Licensure
CA State Medical License 2009 - 2025
NY State Medical License 2000 - 2010- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012
Clinical Trials
- Pemetrexed Disodium With or Without Erlotinib Hydrochloride in Treating Patients With Stage IIIB-IV or Recurrent Non-Small Cell Lung Cancer Start of enrollment: 2006 Apr 01
- CD24Fc for the Treatment of Immune Related Adverse Events in Patients With Advanced Solid Tumors, TIRAEC Study Start of enrollment: 2020 Oct 30
- A Cancer Vaccine (Labvax 3(22)-23) and GM-CSF Alone or in Combination With Pembrolizumab for the Treatment of Advanced Stage Adenocarcinoma Start of enrollment: 2021 Oct 13
Roles: Sponsor-Investigator, Principal Investigator, Contact
Publications & Presentations
PubMed
- 47 citationsAssociation of Epidermal Growth Factor Receptor Activating Mutations with Low ERCC1 Gene Expression in Non-small Cell Lung CancerDavid R. Gandara, Peter P. Grimminger, Philip C. Mack, Primo N. Lara, Tianhong Li
Journal of Thoracic Oncology. 2010-12-01 - 1 citationsSimvastatin Overcomes Resistance to Tyrosine Kinase Inhibitors in Patient-derived, Oncogene-driven Lung Adenocarcinoma Models.Weijie Ma, Weijie Ma, Sixi Wei, Qianping Li, Jie Zeng
Molecular Cancer Therapeutics. 2024-05-02 - 222 citationsManagement of Immunotherapy-Related Toxicities, Version 1.2022, NCCN Clinical Practice Guidelines in Oncology.John A Thompson, Bryan J Schneider, Julie Brahmer, Amaka Achufusi, Philippe Armand
Journal of the National Comprehensive Cancer Network. 2022-04-01
Press Mentions
OncoImmune Launches First-in-Human Clinical Trial for ONC-392 – the Anti-CTLA-4 Antibody That Preserves CTLA4 Recycling for Safer and More Effective ImmunotherapySeptember 23rd, 2020
Liquid, the Latest Advance in the Company’s Liquid Biopsy Test for Solid Tumors in Patients with Advanced CancerSeptember 24th, 2018
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
